



Special Symposium Session 1

EANM & EARL

Sunday, September 10, 16:45 – 18:15

Session Title

Harmonisation and Accreditation Accelerate Research and Clinical Translation

Chairpersons

Sigrid Stroobants (Antwerp, Belgium)

Arturo Chiti (Milan, Italy)

Programme

16:45 - 17:10 **Sigrid Stroobants** (Edegem, Belgium): “To EARL” or “Not To EARL” in clinical practice?

17:10 - 17:40 **Ivalina Hristova** (Vienna, Austria): EARL 1 and EARL 2. Where are we now?

17:40 - 18:10 **Ronald Boellaard** (Amsterdam, The Netherlands): Accreditation for Brain PET studies

18:10 - 18:30 **Johannes Tran-Gia** (Würzburg, Germany): Harmonisation in quantitative SPECT and its challenges

Educational Objectives

1. Learn on the aim and current status of the EARL PET/CT harmonisation program
2. Obtain insights into a strategy to brain PET performance harmonisation
3. Get updated on issues for quantitative SPECT in multicenter studies

Summary

Multi-centre trials are essential in oncology, neurology and beyond to develop and assess the efficacy of new treatments and interventions. Moreover, the use of quantitative imaging biomarkers in both research and care requires them to be reproducible. However, studies involving imaging, heterogeneity in devices and imaging protocols can make data interpretation and application challenging, and indeed mask outcomes that would demonstrate success or failure of the explored hypothesis. In this session, the benefits of harmonization and accreditation for multi-centre trials will be demonstrated, before individual EARL initiatives in oncological and neurological PET, and quantitative SPECT will be described. An update of the current status and challenges facing each of these initiatives will also be given.

Key Words

Imaging biomarkers, Harmonisation, PET, quantitative SPECT